DNMT3A and acute myeloid leukemia: The most common variant mutation of DNMT3A, both in AML and PTCL, is represented by R882, which has been shown to inhibit homotetramer formation, leading to an 80% reduction in DNMT3A activity and a generalized hypomethylation [96].